Human Dihydroorotate Dehydrogenase (hDHODH), a mitochondrial enzyme that plays a pivotal role in the de novo pyrimidine biosynthesis, has been associated to Acute Myelogenous Leukemia (AML), as hDHODH inhibitors are able to restore myeloid differentiation (1). In recent years, we designed potent hDHODH inhibitors applying a scaffold-hopping approach to brequinar’s structure (2). By investigating the lead compound’s SAR, we recently discovered compound 1 (Figure), a candidate superior to brequinar in terms of in vitro potency. Unfortunately, compound 1 showed in vitro metabolic instability, as it soon undergoes to hydroxylation on alkoxy side chain by microsomal enzymes (3). In this occasion, we investigated on the metabolic hydroxylation site through the synthesis of the possible products of microsomal metabolism according to literature (4) and their comparison to compound 1’ s own metabolite in high resolution mass spectrometry (HR-MS); then we designed a new generation of hDHODH inhibitors protected from metabolic oxidation on the alkoxy side chain. Design, synthesis, in vitro metabolism and biological characterization of the new developed compounds are here described and discussed. 1. Sykes, D. B. et al. Inhibition of Dihydroorotate Dehydrogenase Overcomes Differentiation Blockade in Acute Myeloid Leukemia. Cell. 2016, 167(1), 171-186 2. Sainas, S. et al. Targeting Myeloid Differentiation Using Potent 2-Hydroxypyrazolo[1,5- a]pyridine Scaffold-Based Human Dihydroorotate Dehydrogenase Inhibitors. J. Med. Chem. 2018, 61, 6034-6055. 3. Sainas, S. et al. Targeting Acute Myelogenous Leukemia using potent human dihydroorotate dehydrogenase inhibitors based on the 2-hydroxypyrazolo[1,5- a]pyridine scaffold: SAR of the biphenyl moiety. J. Med. Chem. 2021, in press. 4. Testa, B. and Clement, B. Biotransformation Reactions and Their Enzymes. The Practice of Medicinal Chemistry: Fourth Edition. 2015, 561-584.

Targeting Myeloid Leukemias Using human Dihydroorotate Dehydrogenase Inhibitors Based on 2-Hydroxypyrazolo[1,5-a]pyridine Scaffold: Overcoming of Metabolic Issues

Chiara Vigato
First
;
Stefano Sainas;Marta Giorgis;Paola Circosta;Agnese Chiara Pippione;Giuseppe Saglio;Donatella Boschi;Marco Lucio Lolli
Last
2021-01-01

Abstract

Human Dihydroorotate Dehydrogenase (hDHODH), a mitochondrial enzyme that plays a pivotal role in the de novo pyrimidine biosynthesis, has been associated to Acute Myelogenous Leukemia (AML), as hDHODH inhibitors are able to restore myeloid differentiation (1). In recent years, we designed potent hDHODH inhibitors applying a scaffold-hopping approach to brequinar’s structure (2). By investigating the lead compound’s SAR, we recently discovered compound 1 (Figure), a candidate superior to brequinar in terms of in vitro potency. Unfortunately, compound 1 showed in vitro metabolic instability, as it soon undergoes to hydroxylation on alkoxy side chain by microsomal enzymes (3). In this occasion, we investigated on the metabolic hydroxylation site through the synthesis of the possible products of microsomal metabolism according to literature (4) and their comparison to compound 1’ s own metabolite in high resolution mass spectrometry (HR-MS); then we designed a new generation of hDHODH inhibitors protected from metabolic oxidation on the alkoxy side chain. Design, synthesis, in vitro metabolism and biological characterization of the new developed compounds are here described and discussed. 1. Sykes, D. B. et al. Inhibition of Dihydroorotate Dehydrogenase Overcomes Differentiation Blockade in Acute Myeloid Leukemia. Cell. 2016, 167(1), 171-186 2. Sainas, S. et al. Targeting Myeloid Differentiation Using Potent 2-Hydroxypyrazolo[1,5- a]pyridine Scaffold-Based Human Dihydroorotate Dehydrogenase Inhibitors. J. Med. Chem. 2018, 61, 6034-6055. 3. Sainas, S. et al. Targeting Acute Myelogenous Leukemia using potent human dihydroorotate dehydrogenase inhibitors based on the 2-hydroxypyrazolo[1,5- a]pyridine scaffold: SAR of the biphenyl moiety. J. Med. Chem. 2021, in press. 4. Testa, B. and Clement, B. Biotransformation Reactions and Their Enzymes. The Practice of Medicinal Chemistry: Fourth Edition. 2015, 561-584.
2021
EFMC-YMCS 2021: 8th EFMC Young Medicinal Chemists’ Symposium
Virtual Event
9-10 September 2021
-
63
63
Chiara Vigato, Stefano Sainas, Marta Giorgis, Paola Circosta, Alice Passoni, Agnese Chiara Pippione; Renzo Bagnati, Giuseppe Saglio, Donatella Boschi,...espandi
File in questo prodotto:
File Dimensione Formato  
1630930688BookYMCS-Virtual-HD.pdf

Accesso riservato

Descrizione: Book of Abstract
Tipo di file: MATERIALE NON BIBLIOGRAFICO
Dimensione 19.52 MB
Formato Adobe PDF
19.52 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1882163
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact